Altered Invariant Natural Killer T cell Subsets and its Functions in Patients with Oral Squamous Cell Carcinoma

Scandinavian Journal of Immunology

Volumn 78, Issue 5, 2013, Pages 468-477

  Singh, A K ^a   Shukla, N K ^b   Das, S N ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b INSTITUTE ROTARY CANCER HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CD161 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD63 ANTIGEN; CD8 ANTIGEN; CYTOKINE; GAMMA INTERFERON;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CELL ACTIVATION; CELL STRAIN MCF 7; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MALE; MOUTH SQUAMOUS CELL CARCINOMA; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE SUBPOPULATION; TH2 CELL; TUMOR IMMUNITY;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL PROLIFERATION; DENDRITIC CELLS; FEMALE; FLOW CYTOMETRY; GALACTOSYLCERAMIDES; HUMANS; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NATURAL KILLER T-CELLS; PROGNOSIS; T-LYMPHOCYTE SUBSETS; YOUNG ADULT;

EID: 84886737357     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/sji.12104     Document Type: Article

References (39)

1. World Health Organization, The Global Burden of Disease: 2004 Update. Geneva: World Health Organization. (http://www.who.int/healthinfo/global_burden_disease/2004_report _update/en/index.html). Accessed on 25 December 2011. ISBN: 978-92-4-156371-0.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10 (Lyon, France: International Agency for Research on Cancer, 2010). Available from: http://globocan.iarc.fr. Accessed on 26 December 2011
3. Das SN, Khanna NN, Khanna S. In vivo and in vitro observation of cellular immune parameters in squamous cell carcinoma of the oral cavity and its correlation with tumor load and prognosis. Cancer Invest 1986;4:207-16.
4. Manchanda P, Sharma SC, Das SN. Differential regulation of IL-2 and IL-4 in patients with tobacco-related oral squamous cell carcinoma. Oral Dis 2006;12:455-62.
5. Taniguchi M, Harada M, Kojo S, Nakayama T, Wakao H. The regulatory role of Valpha14 NKT cells in innate and acquired immune response. Annu Rev Immunol 2003;21:483-513.
6. Berzins SP, Smyth MJ, Baxter AG. Presumed guilty: natural killer T cell defects and human disease. Nat Rev Immunol 2011;11:131-42.
7. Kobayashi E, Motoki K, Uchida T, Fukushima H, Koezuka Y. KRN7000, a novel immunomodulator, and its antitumor activities. Oncol Res 1995;7:529-34.
8. Kawano T, Cui J, Koezuka Y et al. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 1997;278:1626-9.
9. Brossay L, Chioda M, Burdin N et al. CD1d-mediated recognition of an alpha-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J Exp Med 1998;188:1521-8.
10. Berzofsky JA, Terabe M. NKT cells in tumor immunity: opposing subsets define a new immunoregulatory axis. J Immunol 2008;180:3627-35.
11. Terabe M, Berzofsky JA. The role of NKT cells in tumor immunity. Adv Cancer Res 2008;101:277-348.
12. Yamasaki K, Horiguchi S, Kurosaki M et al. Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy. Clin Immunol 2011;138:255-65.
13. Kawano T, Nakayama T, Kamada N et al. Antitumor cytotoxicity mediated by ligand-activated human V alpha24 NKT cells. Cancer Res 1999;59:5102-5.
14. Tahir SM, Cheng O, Shaulov A et al. Loss of IFN-gamma production by invariant NK T cells in advanced cancer. J Immunol 2001;167:4046-50.
15. Motohashi S, Kobayashi S, Ito T et al. Preserved IFN-alpha production of circulating Valpha24 NKT cells in primary lung cancer patients. Int J Cancer 2002;102:159-65.
16. Crough T, Purdie DM, Okai M, Maksoud A, Nieda M, Nicol AJ. Modulation of human Valpha24(+)Vbeta11(+) NKT cells by age, malignancy and conventional anticancer therapies. Br J Cancer 2004;91:1880-6.
17. Molling JW, Langius JA, Langendijk JA et al. Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma. J Clin Oncol 2007;25:862-8.
18. Metelitsa LS, Wu H-W, Wang H et al. Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2. J Exp Med 2004;199:1213-21.
19. Tachibana T, Onodera H, Tsuruyama T et al. Increased intratumor Valpha24-positive natural killer T cells: a prognostic factor for primary colorectal carcinomas. Clin Cancer Res 2005;11:7322-7.
20. Shaulov A, Yue S, Wang R et al. Peripheral blood progenitor cell product contains Th1-biased noninvariant CD1d-reactive natural killer T cells: implications for posttransplant survival. Exp Hematol 2008;36:464-72.
21. Kenna T, Golden-Mason L, Porcelli SA et al. NKT cells from normal and tumor-bearing human livers are phenotypically and functionally distinct from murine NKT cells. J Immunol 2003;171:1775-9.
22. + Vα24/Vβ11 Invariant NKT Cells in Intrahepatic Malignant Tumors. J Immunol 2009;182:5140-51.
23. Montoya CJ, Pollard D, Martinson J et al. Characterization of human invariant natural killer T subsets in health and disease using a novel invariant natural killer T cell-clonotypic monoclonal antibody, 6B11. Immunology 2007;122:1-14.
24. Exley MA, Hou R, Shaulov A et al. Selective activation, expansion, and monitoring of human iNKT cells with a monoclonal antibody specific for the TCR alpha-chain CDR3 loop. Eur J Immunol 2008;38:1756-66.
25. Edge S, Byrd D, Compton C, Fritz A, Greene F, Trotti A, eds. AJCC Cancer Staging Manual, 7th edn. New York: Springer, 2010: 29-40. ISBN: 978-0-387-88440-0.
26. Dhodapkar KM, Cirignano B, Chamian F et al. Invariant natural killer T cells are preserved in patients with glioma and exhibit antitumor lytic activity following dendritic cell-mediated expansion. Int J Cancer 2004;109:893-9.
27. Lee PT, Benlagha K, Teyton L, Bendelac A. Distinct functional lineages of human V(alpha)24 natural killer T cells. J Exp Med 2002;195:637-41.
28. Gumperz JE, Miyake S, Yamamura T, Brenner MB. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J Exp Med 2002;195:625-36.
29. - CD8αα subset of CD1d-restricted NKT cells controls T cell expansion. J Immunol 2004;172:7350-8.
30. Kasper H-U, Drebber U, Zur Hausen A, Stippel D, Dienes HP, Dries V. Dominance of CD4+ alpha/beta T-cells and inferior role of innate immune reaction in liver metastases. Anticancer Res 2003;23:3175-81.
31. van der Vliet HJ, Molling JW, von Blomberg BME et al. Circulating Valpha24+Vbeta11+ NKT cell numbers and dendritic cell CD1d expression in hepatitis C virus infected patients. Clin Immunol 2005;114:183-9.
32. Marschner A, Rothenfusser S, Hornung V et al. CpG ODN enhance antigen-specific NKT cell activation via plasmacytoid dendritic cells. Eur J Immunol 2005;35:2347-57.
33. Sakakura K, Chikamatsu K, Takahashi K, Whiteside TL, Furuya N. Maturation of circulating dendritic cells and imbalance of T-cell subsets in patients with squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 2006;55:151-9.
34. Crowe NY, Smyth MJ, Godfrey DI. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J Exp Med 2002;196:119-27.
35. Molling JW, Kölgen W, van der Vliet HJ et al. Peripheral blood IFN-gamma-secreting Valpha24+Vbeta11+ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load. Int J Cancer 2005;116:87-93.
36. Yanagisawa K, Seino K, Ishikawa Y, Nozue M, Todoroki T, Fukao K. Impaired proliferative response of V alpha 24 NKT cells from cancer patients against alpha-galactosylceramide. J Immunol 2002;168:6494-9.
37. Smyth MJ, Crowe NY, Hayakawa Y, Takeda K, Yagita H, Godfrey DI. NKT cells - conductors of tumor immunity? Curr Opin Immunol 2002;14:165-71.
38. Tada T, Ohzeki S, Utsumi K et al. Transforming growth factor-beta-induced inhibition of T cell function. Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state. J Immunol 1991;146:1077-82.
39. Agarwal A, Rani M, Saha GK et al. Disregulated expression of the Th2 cytokine gene in patients with intraoral squamous cell carcinoma. Immunol Invest 2003;32:17-30.